Thursday, 5 November 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 4, 2026

Avery Dennison outlines 6% Q1 2026 EPS growth target as high-value category mix accelerates

View original at seekingalpha.com
Avery Dennison outlines 6% Q1 2026 EPS growth target as high-value category mix accelerates Earnings Call Insights: Avery Dennison Corporation (AVY) Q4 2025 MANAGEMENT VIEW * Deon Stander, President, CEO & Director, stated the company delivered adjusted EPS of $9.53 and $707 million of adjusted free cash flow for 2025,…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • We expect restructuring savings of approximately $50 million as we continue to execute our productivity playbook, and we expect the normalization of a majority of the 2025 temporary savings

    80% confidence
  • Base volumes were soft in the quarter, and productivity actions were used to offset wage inflation, with some onetime items and extra calendar days impacting results

    80% confidence
  • Base volumes were a bit soft in the quarter, and productivity actions were used to offset wage inflation, with some onetime items and extra calendar days impacting results

    80% confidence
  • The company delivered adjusted EPS of $9.53 and $707 million of adjusted free cash flow for 2025, emphasizing the durability of our franchise and our ability to activate multiple levers across a range of macro scenarios

    80% confidence
  • Apparel business saw a 7% decline, greater than anticipated, primarily due to changes in retailer ordering behavior amid tariff uncertainty

    80% confidence
  • Expects restructuring benefits to be somewhat balanced across the year

    80% confidence
  • Management is not happy with the organic growth trajectory over the last couple of years

    80% confidence
  • Given key economic indicators remain largely consistent with 2025 levels, the company is not planning for any macroeconomic tailwinds in the near term

    80% confidence
  • Temporary savings headwind is on an order of magnitude basis probably pretty similar to the size of the restructuring actions, that $50 million

    80% confidence
  • High-value categories margins are a number of points above average, significantly above the base categories

    80% confidence
  • Not happy with the way organic growth trajectory has been over the last couple of years

    80% confidence
  • Company continues to drive ongoing productivity all the time in terms of ELS savings, looking at reducing scrap, being more efficient in operations

    80% confidence
  • Q4 delivered solid adjusted earnings per share of $2.45, up 3% compared to prior year

    80% confidence
  • Restructuring benefits expected to be somewhat balanced across the year

    80% confidence
  • Continue to drive ongoing productivity all the time in terms of ELS savings, looking at reducing scrap, being more efficient in operations

    80% confidence
  • Pricing typically follows raw material input cost changes, with productivity actions aimed at offsetting wage inflation

    80% confidence
  • High-value categories now represent 38% of the Materials Group portfolio

    80% confidence
  • High-value categories helped balance base categories, which were down low single digits in the quarter, lower than expected, on softer customer volumes

    80% confidence
  • Expect restructuring savings of approximately $50 million as company continues to execute productivity playbook, and expect normalization of majority of 2025 temporary savings

    80% confidence
  • Anticipating Intelligent Labels growth rate in 2026 to be above what was delivered in 2025, expects high-value categories to grow at mid-single-digit plus

    80% confidence
  • Ongoing investments in digital capabilities, automation, and AI will enable additional operational productivity and fixed cost innovation

    80% confidence
  • The company continues to drive ongoing productivity through ELS savings, reducing scrap, and being more efficient in operations

    80% confidence
  • The company expects restructuring savings of approximately $50 million as it continues to execute its productivity playbook, and expects normalization of a majority of 2025 temporary savings, largely related to lower incentive compensation costs

    80% confidence
  • Walmart rollout would ramp in Q4 2026 and accelerate into 2027

    80% confidence
  • In the fourth quarter, delivered solid adjusted earnings per share of $2.45, up 3% compared to prior year

    80% confidence
  • Solutions Group reported 1.5% sales increase, with high-value categories making up 60% of the portfolio and Vestcom growing over 10%

    80% confidence
  • Pricing typically follows raw material input cost changes, with productivity actions aimed at offsetting wage inflation

    80% confidence
  • Higher working capital was due to high-value category mix, and CapEx will support both productivity and future capacity

    80% confidence
  • The Walmart rollout would ramp in Q4 2026 and accelerate into 2027

    80% confidence
  • Intelligent Labels delivered high single-digit growth

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com
Avery Dennison outlines 6% Q1 2026 EPS growth target as high-value category mix accelerates — Source | Via News | ViaNews EU